17
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Antimicrobial resistance patterns of WHO priority pathogens at general hospital in Southern Ethiopia during the COVID-19 pandemic, with particular reference to ESKAPE-group isolates of surgical site infections

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Antimicrobial resistance represents a significant public health challenge, resulting in an estimated 4.95 million deaths annually. In response to the global escalation of antimicrobial resistance in prevalent hospital-acquired infections such as surgical site infections (SSIs), the World Health Organization (WHO) has identified critical and priority pathogens necessitating research and development. Nevertheless, there remains a paucity of data from numerous developing nations. Therefore this study was conducted to evaluate the prevalence of SSIs, examine the microbial profile, and identify factors associated with SSIs, with a particular emphasis on WHO-priority pathogens during the COVID-19 pandemic at a general hospital in southern Ethiopia.

          Methods

          A cross-sectional study was conducted on 207 adult patients clinically suspected of SSIs from September 1, 2019, to November 2022. Demographic data, clinical characteristics, and surgery-related variables were collected using pre-tested, structured, interviewer-administered questionnaires and patient chart reviews. Wound samples (swabs and/or pus) were collected aseptically from each participant following standard microbiological procedures and processed for isolation and identification of pathogens by conventional culture and biochemical testing. Bacterial isolates subjected to antimicrobial susceptibility testing, including the detection of extended-spectrum beta-lactamase (ESBL) and methicillin-resistant Staphylococcus aureus (MRSA), by the standard Kirby-Bauer disk diffusion method in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines. Data were analyzed by Statistical Packages for Social Science (SPSS) version 25, and bivariable and multivariable logistic regression was done to determine the associations between dependent and independent variables. Adjusted odds ratio with 95% confidence interval (CI) was reported, and P–value < 5% was considered statistically significant.

          Results

          The overall prevalence of culture-confirmed SSIs among adult patients who underwent major surgery was 76.8% (95% CI: 71.0, 82.6). Among the 178 pathogens recovered, 58.5% were Gram-negative, 40.4% were Gram-positive, and 1.1% were Candida spp. The ESKAPE pathogens comprised 65.3% of the isolates, with S. aureus being the most common species, accounting for 43.5%, followed by K. pneumoniae (33.9%). Multidrug resistance (MDR) was observed in 84.37% of ESKAPE pathogens, with ESBL-producing and MRSA-producing isolates accounting for 88% and 76.5%, respectively. A. baumannii showed the highest MDR rate at 100%, followed by MRSA (90%) and K. pneumoniae (88.23%). Amikacin, meropenem, and piperacillin-tazobactam were effective agents against Gram-negatives, while linezolid, clindamycin, and gentamicin were most effective against Gram-positive bacteria. SSIs was significantly associated with emergency surgery ( P < 0.001), prolonged surgery waiting time ( P = 0.004), and clean-contaminated surgery ( P = 0.008).

          Conclusion

          The high prevalence of MDR-ESKAPE pathogens is concerning, highlighting the need for improved infection prevention practices and antimicrobial stewardship programs.

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s12866-025-03783-1.

          Related collections

          Most cited references50

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis

          (2022)
          Summary Background Antimicrobial resistance (AMR) poses a major threat to human health around the world. Previous publications have estimated the effect of AMR on incidence, deaths, hospital length of stay, and health-care costs for specific pathogen–drug combinations in select locations. To our knowledge, this study presents the most comprehensive estimates of AMR burden to date. Methods We estimated deaths and disability-adjusted life-years (DALYs) attributable to and associated with bacterial AMR for 23 pathogens and 88 pathogen–drug combinations in 204 countries and territories in 2019. We obtained data from systematic literature reviews, hospital systems, surveillance systems, and other sources, covering 471 million individual records or isolates and 7585 study-location-years. We used predictive statistical modelling to produce estimates of AMR burden for all locations, including for locations with no data. Our approach can be divided into five broad components: number of deaths where infection played a role, proportion of infectious deaths attributable to a given infectious syndrome, proportion of infectious syndrome deaths attributable to a given pathogen, the percentage of a given pathogen resistant to an antibiotic of interest, and the excess risk of death or duration of an infection associated with this resistance. Using these components, we estimated disease burden based on two counterfactuals: deaths attributable to AMR (based on an alternative scenario in which all drug-resistant infections were replaced by drug-susceptible infections), and deaths associated with AMR (based on an alternative scenario in which all drug-resistant infections were replaced by no infection). We generated 95% uncertainty intervals (UIs) for final estimates as the 25th and 975th ordered values across 1000 posterior draws, and models were cross-validated for out-of-sample predictive validity. We present final estimates aggregated to the global and regional level. Findings On the basis of our predictive statistical models, there were an estimated 4·95 million (3·62–6·57) deaths associated with bacterial AMR in 2019, including 1·27 million (95% UI 0·911–1·71) deaths attributable to bacterial AMR. At the regional level, we estimated the all-age death rate attributable to resistance to be highest in western sub-Saharan Africa, at 27·3 deaths per 100 000 (20·9–35·3), and lowest in Australasia, at 6·5 deaths (4·3–9·4) per 100 000. Lower respiratory infections accounted for more than 1·5 million deaths associated with resistance in 2019, making it the most burdensome infectious syndrome. The six leading pathogens for deaths associated with resistance (Escherichia coli, followed by Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa) were responsible for 929 000 (660 000–1 270 000) deaths attributable to AMR and 3·57 million (2·62–4·78) deaths associated with AMR in 2019. One pathogen–drug combination, meticillin-resistant S aureus, caused more than 100 000 deaths attributable to AMR in 2019, while six more each caused 50 000–100 000 deaths: multidrug-resistant excluding extensively drug-resistant tuberculosis, third-generation cephalosporin-resistant E coli, carbapenem-resistant A baumannii, fluoroquinolone-resistant E coli, carbapenem-resistant K pneumoniae, and third-generation cephalosporin-resistant K pneumoniae. Interpretation To our knowledge, this study provides the first comprehensive assessment of the global burden of AMR, as well as an evaluation of the availability of data. AMR is a leading cause of death around the world, with the highest burdens in low-resource settings. Understanding the burden of AMR and the leading pathogen–drug combinations contributing to it is crucial to making informed and location-specific policy decisions, particularly about infection prevention and control programmes, access to essential antibiotics, and research and development of new vaccines and antibiotics. There are serious data gaps in many low-income settings, emphasising the need to expand microbiology laboratory capacity and data collection systems to improve our understanding of this important human health threat. Funding Bill & Melinda Gates Foundation, Wellcome Trust, and Department of Health and Social Care using UK aid funding managed by the Fleming Fund.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.

            Many different definitions for multidrug-resistant (MDR), extensively drug-resistant (XDR) and pandrug-resistant (PDR) bacteria are being used in the medical literature to characterize the different patterns of resistance found in healthcare-associated, antimicrobial-resistant bacteria. A group of international experts came together through a joint initiative by the European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC), to create a standardized international terminology with which to describe acquired resistance profiles in Staphylococcus aureus, Enterococcus spp., Enterobacteriaceae (other than Salmonella and Shigella), Pseudomonas aeruginosa and Acinetobacter spp., all bacteria often responsible for healthcare-associated infections and prone to multidrug resistance. Epidemiologically significant antimicrobial categories were constructed for each bacterium. Lists of antimicrobial categories proposed for antimicrobial susceptibility testing were created using documents and breakpoints from the Clinical Laboratory Standards Institute (CLSI), the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the United States Food and Drug Administration (FDA). MDR was defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories, XDR was defined as non-susceptibility to at least one agent in all but two or fewer antimicrobial categories (i.e. bacterial isolates remain susceptible to only one or two categories) and PDR was defined as non-susceptibility to all agents in all antimicrobial categories. To ensure correct application of these definitions, bacterial isolates should be tested against all or nearly all of the antimicrobial agents within the antimicrobial categories and selective reporting and suppression of results should be avoided. © 2011 European Society of Clinical Microbiology and Infectious Diseases. No claim to original US government works.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

              The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and mortality worldwide. Due to its large public health and societal implications, multidrug-resistant tuberculosis has been long regarded by WHO as a global priority for investment in new drugs. In 2016, WHO was requested by member states to create a priority list of other antibiotic-resistant bacteria to support research and development of effective drugs.
                Bookmark

                Author and article information

                Contributors
                mohamedseid2005@gmail.com
                Journal
                BMC Microbiol
                BMC Microbiol
                BMC Microbiology
                BioMed Central (London )
                1471-2180
                22 February 2025
                22 February 2025
                2025
                : 25
                : 84
                Affiliations
                [1 ]Department of Medical Laboratory Science, College of Medicine and Health Sciences, Arba Minch University, ( https://ror.org/00ssp9h11) Arba Minch, Ethiopia
                [2 ]School of Medicine, College of Medicine and Health Sciences, Arba Minch University, ( https://ror.org/00ssp9h11) Arba Minch, Ethiopia
                [3 ]Department of Medical Laboratory Science, Arba Minch, College of Health Sciences, Arba Minch, Ethiopia
                [4 ]Arba Minch General Hospital, Arba Minch, Ethiopia
                [5 ]Department of Botany and Microbiology, College of Science, King Saud University, ( https://ror.org/02f81g417) P.O. Box 2455, Riyadh, 11451 Saudi Arabia
                [6 ]Research Department of Chemistry, Nehru Memorial College (Affiliated to Bharathidasan University), ( https://ror.org/02w7vnb60) Puthanampatti, Tiruchirappalli District, Tamil Nadu 621007 India
                Article
                3783
                10.1186/s12866-025-03783-1
                11846185
                39987036
                55632bd9-e80b-47be-9d93-d89e67fa9a8e
                © The Author(s) 2025

                Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

                History
                : 19 September 2024
                : 23 January 2025
                Categories
                Research
                Custom metadata
                © BioMed Central Ltd., part of Springer Nature 2025

                Microbiology & Virology
                general surgery,surgical site infections,antimicrobial resistance,nosocomial infections,who-priority pathogens,developing country,ethiopia

                Comments

                Comment on this article